Cure8 news brief
Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and insurer uptake can affect patient access and insurance coverage timing.
Adult patients with IBD, patients on biologics, gastroenterology clinicians, and researchers tracking IBD treatment market trends.
AbbVie’s Q2 2026 revenue strength was driven by two immunology drugs, Skyrizi (risankizumab) and Rinvoq (upadacitinib), with strong sales growth and market-share gains in IBD (Crohn’s disease and ulcerative colitis).
The company raised its Skyrizi sales outlook and noted continued momentum for Rinvoq in gastroenterology; regulatory milestones mentioned include a U.S. decision awaited for a subcutaneous Skyrizi induction regimen in Crohn’s disease and pending U.S. reviews for Rinvoq dermatology indications.
This is a business/market report summarizing corporate sales, forecasts, competition, and regulatory timing rather than new clinical data. It highlights how new indications, launches, and route-of-administration changes can affect drug uptake and company revenue.
If you follow IBD treatment trends, this article signals that risankizumab and upadacitinib are growing players in IBD and that payer/reimbursement timing may influence when changes in prescribing reach patients.
This is market/financial reporting (Zacks/TradingView) summarizing company sales, forecasts, and regulatory expectations — not a clinical study. Regulatory decisions and insurance/reimbursement rollouts drive real-world access timing; business projections do not equal demonstrated superior clinical outcomes.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
